Why AbbVie (ABBV) Is Considered a Top Long‑Term Value Stock

AbbVie Inc. (NYSE: ABBV), the large U.S. biopharmaceutical company known for drugs such as Humira, Skyrizi and Rinvoq, is drawing attention as a compelling long‑term value stock for investors. According to **Zacks Investment Research**, AbbVie currently holds a **Zacks Rank of #3 (Hold)** and carries solid **Value and VGM (Value‑Growth‑Momentum) Style Scores of B**, suggesting its share price may be undervalued relative to fundamentals. Shares trade at an attractive forward price‑to‑earnings ratio of about 15.5×, which helps drive its strong Value Style Score and appeals to value‑focused investors. In addition, recent earnings estimate revisions have trended positively, with the Zacks Consensus Estimate for 2025 earnings per share rising modestly, and the company maintaining a positive track record of earnings surprises. AbbVie’s transformation after its acquisition of Allergan in 2020 reduced reliance on Humira after patent expiries, with newer immunology drugs Skyrizi and Rinvoq now key growth drivers. These products, alongside a broad therapeutic portfolio and attractive valuation metrics, make AbbVie a stock that investors seeking value may want to consider for the long term. #AbbVie #ValueStock #Investing #PharmaStocks #SlimScan #GrowthStocks #CANSLIM